Safety and efficacy of tibolone and menopausal transition: A randomized, double-blind placebo-controlled trial

Gynecological Endocrinology

Volumn 28, Issue 6, 2012, Pages 483-487

  Maria, Morais Socorro ^a   Alvaro, Cavalcanti MacIel ^a   Rand, Martins ^a   Paulo, Neto Francisco ^a   Adriana, Rezende ^a   George, Azevedo ^a   Maria, Almeida ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

Endometrium; Hormone replacement therapy; Menopausal transition; Menopause; Tibolone

Indexed keywords

ESTRADIOL; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TIBOLONE; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; ARTICLE; BLATT KUPPERMAN MENOPAUSAL INDEX; BREAST TENDERNESS; CHOLESTEROL BLOOD LEVEL; CLIMACTERIUM; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM; ENDOMETRIUM ATROPHY; FEMALE; FOLLITROPIN BLOOD LEVEL; GLYCEMIC INDEX; GREENE CLIMACTERIC SCALE; HUMAN; LIPID BLOOD LEVEL; LIVER FUNCTION; MAJOR CLINICAL STUDY; MASTALGIA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; VAGINA BLEEDING;

ADMINISTRATION, ORAL; ADULT; DOUBLE-BLIND METHOD; ENDOMETRIUM; ESTROGEN RECEPTOR MODULATORS; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; NORPREGNENES; ORGAN SIZE; PLACEBOS; TREATMENT OUTCOME;

EID: 84861048377     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.634937     Document Type: Article

References (34)

1. Nejat EJ, Chervenak JL. The continuum of ovarian aging and clinicopathologies associated with the menopausal transition. Maturitas 2010;66:187-190.
2. Gracia CR, Sammel MD, Freeman EW, Lin H, Langan E, Kapoor S, Nelson DB. Defining menopause status: Creation of a new definition to identify the early changes of the menopausal transition. Menopause 2005;12:128-135. (Pubitemid 40464279)
3. Santoro N, Chervenak JL. The menopause transition. Endocrinol Metab Clin North Am 2004;33:627-636. (Pubitemid 39388978)
4. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, Woods N. Stages of Reproductive Aging Workshop (STRAW). J Womens Health Gend Based Med 2001;10:843-848. (Pubitemid 33138765)
5. Maclennan AH. Evidence-based review of therapies at the menopause. Int J Evid Based Healthc 2009;7:112-123.
6. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242-255.
7. Kenemans P, Speroff L; International Tibolone Consensus Group. Tibolone: Clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005;51:21-28. (Pubitemid 40692595)
8. Huang KE, Baber R; Asia Pacific Tibolone Consensus Group. Updated clinical recommendations for the use of tibolone in Asian women. Climacteric 2010;13:317-327.
9. Modelska K, Cummings S. Tibolone for postmenopausal women: Systematic review of randomized trials. J Clin Endocrinol Metab 2002; 87:16-23. (Pubitemid 34084663)
10. Biglia N, Maffei S, Lello S, Nappi RE. Tibolone in postmenopausal women: A review based on recent randomised controlled clinical trials. Gynecol Endocrinol 2010;26:804-814.
11. El-Hajj Fuleihan G. Tibolone and the promise of ideal hormonereplacement therapy. N Engl J Med 2008;359:753-755.
12. Albertazzi P, Di Micco R, Zanardi E. Tibolone: A review. Maturitas 1998;30:295-305. (Pubitemid 28526436)
13. Kloosterboer HJ. Tissue-selectivity: The mechanism of action of tibolone. Maturitas 2004;48(Suppl 1):30-40.
14. Swanson SG, Drosman S, Helmond FA, Stathopoulos VM. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: A multicenter, randomized, double-blind, placebo-controlled study. Menopause 2006;13:917-925. (Pubitemid 44760384)
15. Obenauer S, Hermann KP, Grabbe E. Applications and literature review of the BI-RADS classification. Eur Radiol 2005;15:1027-1036. (Pubitemid 41166736)
16. Somunkiran A, Erel CT, Demirci F, Senturk ML. The effect of tibolone versus 17?-estradiol on climacteric symptoms in women with surgical menopause: A randomized, cross-over study. Maturitas 2007;56:61-68. (Pubitemid 44894789)
17. Azevedo GD, Prado MFM, Ferriani RA, Reis RM, Berezowski AT, Maranhao TMO, et al. Raloxifene therapy does not affect uterine blood flow in postmenopausal: A transvaginal Doppler study. Maturitas 2004;47:195-200. (Pubitemid 38270397)
18. Azevedo GD, Silveira IL, Petronillo PA, Souza MO, Costa e Silva TDN et al. Prevalencia de Sintomas do Climaterio em mulheres dos meios rural e urbano do Rio Grande do Norte, Brasil. Rev Bras Ginecol Obstet 2007;29:420-427.
19. Freitas AK, Freitas RA Jr, Prado MF, Azevedo GD, Foss MC, Silva-de-Sa MF, Ferriani RA. [Tibolone treatment of diabetic postmenopausal women: Clinical and laboratory safety parameters]. Arq Bras Endocrinol Metabol 2005;49:433-440.
20. Nijland EA, Nathorst-Boos J, Palacios S, van de Weijer PW, Davis S, Stathopoulos VM, Birkhaeuser MH, et al.; LISA study investigators group. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. Climacteric 2009;12:114-121.
21. Doren M, Rubig A, Coelingh Bennink HJ, Holzgreve W. Impact on uterine bleeding and endometrial thickness: Tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999;6:299-306. (Pubitemid 30003272)
22. Christodoulakos GE, Botsis DS, Lambrinoudaki IV, Papagianni VD, Panoulis CP, Creatsa MG, Alexandrou AP, et al. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Maturitas 2006;53:413-423.
23. Greene JG. Constructing a standard climacteric scale. Maturitas 1998;29:25-31. (Pubitemid 28247565)
24. Alder E. The Blatt-Kupperman menopausal index: A critique. Maturitas 1998;29:19-24. (Pubitemid 28247564)
25. Landgren MB, Bennink HJ, Helmond FA, Engelen S. Dose-response analysis of effects of tibolone on climacteric symptoms. BJOG 2002;109:1109-1114. (Pubitemid 35287079)
26. Escande A, Servant N, Rabenoelina F, Auzou G, Kloosterboer H, Cavailles V, Balaguer P, Maudelonde T. Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites. J Steroid Biochem Mol Biol 2009;116:8-14.
27. Lam PM, Cheung GW, Shek DT, Lee DT, Haines CJ, Chung TK. Arandomized, placebo-controlled, crossover study of tibolone (Livial) on menopause symptoms, psychological well-being, and dyadic relationship of postmenopausal Chinese women and their spouses. Menopause 2004;11:416-422. (Pubitemid 40362165)
28. Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, Grobbee DE; OPAL Investigators. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J 2006;27:746-755.
29. Stuckey BG, Barrett PH, Wagner JM, Hampton RA, Chan DC, Brown SJ, Watts GF. The effect of fenofibrate on HDL cholesterol and HDL particle concentration in postmenopausal women on tibolone therapy. Clin Endocrinol (Oxf) 2010;73:497-501.
30. Kloosterboer HJ, Benedek-Jaszmann LJ, Kicovic PM. Long-term effects of Org OD 14 on lipid metabolism in post-menopausal women. Maturitas 1990;12:37-42. (Pubitemid 20138792)
31. Crona N, Silfverstolpe G, Samsioe G. A double-blind cross-over study on the effects of ORG OD14 compared to oestradiol valerate and placebo on lipid and carbohydrate metabolism in oophorectomized women. Acta Endocrinol 1983;102:451-455. (Pubitemid 13144778)
32. Wiegratz I, Starflinger F, Tetzloff W, Leifels-Fischer B, Helmond FA, Dericks-Tan JS, Kuhl H. Effect of tibolone compared with sequential hormone replacement therapy on carbohydrate metabolism in postmenopausal women. Maturitas 2002;41:133-141.
33. Huber J, Palacios S, Berglund L, Hanggi W, Sathanandan SM, Christau S, Helmond F. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 2002;109:886-893. (Pubitemid 37337967)
34. Meuwissen JH, Wiegerinck MA, Haverkorn MJ. Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy. Maturitas 1995;21: 121-125.